The link between abdominal obesity and the metabolic syndrome
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
The clustering of cardiovascular risk factors associated with abdominal obesity is well established. Although currently lacking a universal definition, the metabolic syndrome describes a constellation of metabolic abnormalities, including abdominal obesity, and was originally introduced to characterize a population at high cardiovascular risk. Adipose tissue is a dynamic endocrine organ that secretes several inflammatory and immune mediators known as adipokines. Dysregulation of adipokine secretion, free fatty acid toxicity, and the site-specific differences in abdominal (visceral) versus subcutaneous fat support abdominal obesity as a causal factor mediating the insulin resistance, increased risk of diabetes, and cardiovascular disease in the metabolic syndrome.
- World Health Organization: Global strategy on diet, physical activity and health. Available at: http://www.who.int/dietphysicalactivity/publications/facts/obesity/en/. Accessed November 2007.
- Vague J: The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 1956, 4:20–34.
- Wajchenberg BL: Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000, 21:697–738. CrossRef
- Alberti KG, Zimmet P, Shaw J: The metabolic syndrome—a new worldwide definition. Lancet 2005, 366:1059–1062. CrossRef
- Grundy SM, Cleeman JI, Daniels SR, et al.: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735–2752. CrossRef
- Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548–2556. CrossRef
- Hotamisligil GS: Inflammation and metabolic disorders. Nature 2006, 444:860–867. CrossRef
- Weisberg SP, McCann D, Desai M, et al.: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796–1808.
- Xu H, Barnes GT, Yang Q, et al.: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112:1821–1830.
- Kahn R, Buse J, Ferrannini E, Stern M: The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28:2289–2304. CrossRef
- Galassi A, Reynolds K, He J: Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006, 119:812–819. CrossRef
- Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus. In Report of a WHO Consultation. Geneva: World Health Organization, Department of Noncommunicable Disease Surveillance; 1999:1–59.
- Ford ES: Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005, 28:2745–2749. CrossRef
- Rosen ED, Spiegelman BM: Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006, 444:847–853. CrossRef
- Badman MK, Flier JS: The adipocyte as an active participant in energy balance and metabolism. Gastroenterology 2007, 132:2103–2115. CrossRef
- Whitehead JP, Richards AA, Hickman IJ, et al.: Adiponectin—a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006, 8:264–280. CrossRef
- Richards AA, Stephens T, Charlton HK, et al.: Adiponectin multimerization is dependent on conserved lysines in the collagenous domain: evidence for regulation of multimerization by alterations in posttranslational modifications. Mol Endocrinol 2006, 20:1673–1687. CrossRef
- Yamauchi T, Kamon J, Ito Y, et al.: Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423:762–769. CrossRef
- Yamauchi T, Kamon J, Minokoshi Y, et al.: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002, 8:1288–1295. CrossRef
- Kubota N, Yano W, Kubota T, et al.: Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab 2007, 6:55–68. CrossRef
- Hug C, Wang J, Ahmad NS, et al.: T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci U S A 2004, 101:10308–10313. CrossRef
- Takemura Y, Ouchi N, Shibata R, et al.: Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J Clin Invest 2007, 117:375–386. CrossRef
- Yamauchi T, Nio Y, Maki T, et al.: Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007, 13:332–339. CrossRef
- Xu A, Wang Y, Keshaw H, et al.: The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003, 112:91–100.
- Covey SD, Wideman RD, McDonald C, et al.: The pancreatic beta cell is a key site for mediating the effects of leptin on glucose homeostasis. Cell Metab 2006, 4:291–302. CrossRef
- Chen K, Li F, Li J, et al.: Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med 2006, 12:425–432. CrossRef
- Farooqi IS, O’Rahilly S: Is leptin an important physiological regulator of CRP? Nat Med 2007, 13:16–17; author reply 19–21. CrossRef
- Fukuhara A, Matsuda M, Nishizawa M, et al.: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005, 307:426–430. CrossRef
- Varma V, Yao-Borengasser A, Rasouli N, et al.: Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J Clin Endocrinol Metab 2007, 92:666–672. CrossRef
- Stephens JM, Vidal-Puig AJ: An update on visfatin/pre-B cell colony-enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity. Curr Opin Lipidol 2006, 17:128–131. CrossRef
- Ingelsson E, Larson MG, Fox CS, et al.: Clinical correlates of circulating visfatin levels in a community-based sample. Diabetes Care 2007, 30:1278–1280. CrossRef
- Korner A, Garten A, Bluher M, et al.: Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 2007, 92:4783–4791. CrossRef
- Yang RZ, Lee MJ, Hu H, et al.: Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006, 290:E1253–E1261. CrossRef
- de Souza Batista CM, Yang RZ, Lee MJ, et al.: Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007, 56:1655–1661. CrossRef
- Ma LJ, Mao SL, Taylor KL, et al.: Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004, 53:336–346. CrossRef
- Hida K, Wada J, Eguchi J, et al.: Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A 2005, 102:10610–10615. CrossRef
- Seeger J, Ziegelmeier M, Bachmann A, et al.: serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab 2008, 93:247–251. CrossRef
- Bernstein LE, Berry J, Kim S, et al.: Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 2006, 166:902–908. CrossRef
- Arkan MC, Hevener AL, Greten FR, et al.: IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005, 11:191–198. CrossRef
- Weisberg SP, Hunter D, Huber R, et al.: CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 2006, 116:115–124. CrossRef
- Kanda H, Tateya S, Tamori Y, et al.: MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006, 116:1494–1505. CrossRef
- Desbriere R, Vuaroqueaux V, Achard V, et al.: 11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring) 2006, 14:794–798. CrossRef
- Shi H, Kokoeva MV, Inouye K, et al.: TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006, 116:3015–3025. CrossRef
- Nielsen S, Guo Z, Johnson CM, et al.: Splanchnic lipolysis in human obesity. J Clin Invest 2004, 113:1582–1588.
- Fain JN, Madan AK, Hiler ML, et al.: Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004, 145:2273–2282. CrossRef
- Aronne LJ: Therapeutic options for modifying cardiometabolic risk factors. Am J Med 2007, 120:S26–S34. CrossRef
- Barzilai N, She L, Liu BQ, et al.: Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes 1999, 48:94–98. CrossRef
- Klein S, Fontana L, Young VL, et al.: Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004, 350:2549–2557. CrossRef
- Guarente L: Sirtuins as potential targets for metabolic syndrome. Nature 2006, 444:868–874. CrossRef
- Nuotio-Antar AM, Hachey D, Hasty AH: Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice. Am J Physiol Endocrinol Metab 2007, 293:E1517–E1528. CrossRef
- The link between abdominal obesity and the metabolic syndrome
Current Hypertension Reports
Volume 10, Issue 2 , pp 156-164
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Industry Sectors